SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC Keeping it real board for pro and con discussions
NNVC 1.220-3.2%Nov 28 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Rawnoc12/28/2014 1:07:59 PM
  Read Replies (1) of 326
 
Here is a company blazing ahead of NNVC:

ansunbiopharma.com

Phase 3 human trials with a drug that seems quite impressive. Scored over $90 million in government funding just for its flu drug from places such as the Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health.

The drug, Fludase, is taken with an inhaler so it goes right to the localized place where the flu reproduces -- the respiratory epithelial cells -- or the lungs, throat, etc.

Mice were given lethal doses of flu virus. 100% of the placebo group died. 100% of the Fludase group recovered fully and lived for most strains though for swine flu it was only 90%. Delayed treatments (more than 48 hours after infection) had lower survival rates but still over 75%.

The phase 1 and phase 2 studies in HUMANS were a raging success. Viral load down as much as more than 10,000 fold with few serious side effects and no more vs. the placebo. However, what has yet to be proven is if a drastic reduction in the viral load and symptoms in humans leads to a higher survival rate. Of course, that's the theory behind NNVC's Flucide too so if it fails with Fludase it will likely fail with Flucide.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext